Buckley Mitchell S, Benanti Grace E, Meckel Jordan, Tekle Luwam A, Gilbert Brian, Puebla Neira Daniel, McNierney Dakota A, Korkames Grace, Yerondopoulos Melanie, Park Andrew, O'Hea Jennifer A, MacLaren Robert
Department of Pharmacy, Banner University Medical Center Phoenix, Phoenix, Arizona, USA.
Department of Pharmacy, Loyola University Medical Center, Maywood, Illinois, USA.
Pharmacotherapy. 2023 Mar;43(3):196-204. doi: 10.1002/phar.2776. Epub 2023 Feb 22.
Thromboelastography (TEG) offers a more dynamic assessment of hemostasis over activated partial thromboplastin time (aPTT). However, the clinical utility of TEG in monitoring bivalirudin during extracorporeal membrane oxygenation (ECMO) remains unknown. The purpose of this study was to evaluate the correlation between aPTT and TEG in adult ECMO patients anticoagulated with bivalirudin.
Multicenter, retrospective, cohort study conducted over a 2-year period.
Two academic university medical centers (Banner University Medical Center) in Phoenix and Tucson, AZ.
Adult patients requiring ECMO and bivalirudin therapy with ≥1 corresponding standard TEG and aPTT plasma samples drawn ≤4 h of each other were included. The primary endpoint was to determine the correlation coefficient between the standard TEG reaction (R) time and bivalirudin aPTT serum concentrations.
A total of 104 patients consisting of 848 concurrent laboratory assessments of R time and aPTT were included. A moderate correlation between TEG R time and aPTT was demonstrated in the study population (r = 0.41; p < 0.001). Overall, 502 (59.2%) concurrent assessments of TEG R time and aPTT values showed agreement on whether they were sub-, supra-, or therapeutic according to the institution's classification for bivalirudin. The 42.2% (n = 271/642) discordant TEG R times among "therapeutic" aPTT were almost equally distributed between subtherapeutic and supratherapeutic categories.
Moderate correlation was found between TEG R time and aPTT associated with bivalirudin during ECMO in critically ill adults. Further research is warranted to address the optimal test to guide clinical decision-making for anticoagulation dosing in ECMO patients.
与活化部分凝血活酶时间(aPTT)相比,血栓弹力图(TEG)能更动态地评估止血功能。然而,TEG在体外膜肺氧合(ECMO)期间监测比伐卢定的临床效用尚不清楚。本研究的目的是评估接受比伐卢定抗凝的成年ECMO患者中aPTT与TEG之间的相关性。
为期2年的多中心回顾性队列研究。
亚利桑那州凤凰城和图森市的两家学术性大学医学中心(班纳大学医学中心)。
纳入需要ECMO和比伐卢定治疗且有≥1份相应标准TEG和aPTT血浆样本(采集时间相隔≤4小时)的成年患者。主要终点是确定标准TEG反应(R)时间与比伐卢定aPTT血清浓度之间的相关系数。
共纳入104例患者,对其进行了848次R时间和aPTT的同步实验室评估。研究人群中TEG R时间与aPTT之间存在中度相关性(r = 0.41;p < 0.001)。总体而言,根据机构对比伐卢定的分类,502次(59.2%)TEG R时间与aPTT值的同步评估在它们是低于、高于还是处于治疗范围方面显示出一致性。在“治疗性”aPTT中,42.2%(n = 271/642)不一致的TEG R时间在低于治疗范围和高于治疗范围类别之间分布几乎相等。
在危重症成年患者的ECMO期间,发现TEG R时间与比伐卢定相关的aPTT之间存在中度相关性。有必要进行进一步研究以确定指导ECMO患者抗凝剂量临床决策的最佳检测方法。